Malotilate (Synonyms: NKK-105) |
| Catalog No.GC14751 |
말로틸레이트(NKK 105), 경구 활성 간기능 강화제 및 항섬유화 물질은 5-리폭시게나제(5-LOX)(IC50=4.7μM)를 선택적으로 억제합니다. Malotilate는 간의 아세트알데히드 수치를 감소시키고 간세포에서 트랜스페린의 체류를 방지함으로써 알코올-피라졸 간염에서 간세포 손상의 발병을 예방합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 59937-28-9
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
IC50: N/A
Malotilate (diisopropyl-l,3-dithiol-2-ylidenemalonate) is a novel hepatotrophic drug, which can improve protein metabolism and stimulate hepatocyte regeneration.
In vitro: The in-vitro invasion assay employing a rat lung endothelial cell monolayer indicated that pretreatment of the lung endothelial cells, but not c-SST-2 cells, with malotilate reduced the invasion of the RLE monolayer by c-SST-2 cells significantly. The in-vitro vascular permeability assay also demonstrated malotilate could prevent the permeability increase of the lung endothelial cell monolayer by serum starvation. In contrast, the gelatinase production and adhesion to the RLE cell monolayer of c-SST-2 cells were not affected by malotilate treatment [1].
In vivo: Malotilate was administered to syngeneic SHR rats orally from 7 days before or after s.c. inoculation of c-SST-2 cells until the end of the experiments. In the malotilate-treated rats, pulmonary metastasis was suppressed markedly when compared with the non-treated rats. Moreover, in the rats treated with malotilate for 19 days after inoculation of c-SST-2 cells, lung metastasis was also suppressed significantly [1].
Clinical trial: A previous clinical trial results indicated that malotilate could accelerate the recovery of impaired protein metabolism in alcoholic liver disease and thus malotilate might be useful for the treatment of alcoholic liver diseases [2].
References:
[1] Nagayasu H,Hamada J,Kawano T,Konaka S,Nakata D,Shibata T,Arisue M,Hosokawa M,Takeichi N,Moriuchi T. Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. Br J Cancer.1998 May;77(9):1371-7.
[2] Takase S,Matsuda Y,Yasuhara M,Takada A. Effects of malotilate treatment on alcoholic liver disease. Alcohol.1989 May-Jun;6(3):219-22.
| Cas No. | 59937-28-9 | SDF | |
| Synonyms | NKK-105 | ||
| Chemical Name | dipropan-2-yl 2-(1,3-dithiol-2-ylidene)propanedioate | ||
| Canonical SMILES | CC(C)OC(=O)C(=C1SC=CS1)C(=O)OC(C)C | ||
| Formula | C12H16O4S2 | M.Wt | 288.38 |
| Solubility | ≥ 14.4mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4676 mL | 17.3382 mL | 34.6765 mL |
| 5 mM | 0.6935 mL | 3.4676 mL | 6.9353 mL |
| 10 mM | 0.3468 mL | 1.7338 mL | 3.4676 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *